Emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg tablets (Laurus Labs Ltd), HA717

LABELLING

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING HDPE Bottle

1. Name of the medicinal product

[HA717 trade name]* Emtricitabine/Tenofovir disoproxil fumarate 200 mg/300 mg Tablets

2. Statement of active substance

Each film-coated tablet contains 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate.

3. List of excipients

Each film-coated tablet contains 145 mg of lactose anhydrous and 8.4mg of lactose monohydrate.

See patient information leaflet for further information.

4. Pharmaceutical form and contents

Film-coated tablets

30 Tablets

90 Tablets

5. Method and route of administration

Oral use.

Do not chew.

Read the patient information leaflet before use.

6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep out of the reach of children.

7. Other special warning(s), if necessary

8. Expiry date

EXP {MM/YYYY}

9. Special storage conditions

Do not store above 30°C. Store in the original container. Keep the bottle tightly closed.

10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate

Emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg tablets (Laurus Labs Ltd), HA717

11. Name and address of the supplier

Laurus Labs Limited 2nd Floor, serene Chambers, Road No.7 Banjara hills, Hyderabad, Telangana- 500034 India

12. WHO Reference Number (Prequalification Programme)

HA717

13. Manufacturer's batch number

<Batch> <Lot> {number}

14. (Advice on) General classification for supply

Medicinal product subject to medical prescription.

15. Instructions on use